Clinical Trials
78 trialsASCEND
Australasian Gastro-Intestinal Trials Group
Surufatinib Combined With KN046 and AG Regimen Chemotherapy as First-Line Treatment for Unresectable Advanced Pancreatic Cancer
Shanghai Zhongshan Hospital
Modified FOLFIRINOX Alternated With Biweekly Gemcitabine Plus Nab-Paclitaxel Untreated Pancreatic Cancer
Rutgers, The State University of New Jersey
Neoadjuvant CCRT With Gemcitabine/Durvalumab (MEDI4736) Followed by Adjuvant Gemcitabine/Durvalumab(MEDI4736) in Resectable or Borderline Resectable Pancreatic Cancer
Seoul National University Hospital
Pembrolizumab Plus Chemotherapy in 1st Line Treatment of Pancreatic Cancer
Seoul National University Hospital
C3
State University of New York - Downstate Medical Center
A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer
Sun Yat-sen University
MIKE-1
Nagoya University
A Study of GB201 in Combination With Weekly Paclitaxel and Low-dose Gemcitabine in Patients With Pancreatic Cancer
1Globe Biomedical Co., Ltd.
A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer
RenJi Hospital
Peri-operative SLOG for Localized Pancreatic Cancer
National Health Research Institutes, Taiwan
RP72 Monotherapy and in Combination With Gemcitabine in Patients With Pancreatic Cancer
Rise Biopharmaceuticals, Inc.
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer
Changhai Hospital
Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Recurrent Pancreatic Cancer
Changhai Hospital
Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic Cancer
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Concurrent Chemoradiotherapy Combined With Immunotherapy in Patients With Potentially Resectable Pancreatic Cancer
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
FOOTPATH
Ludwig-Maximilians - University of Munich
SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer
Ruijin Hospital
MASTERPLAN
Australasian Gastro-Intestinal Trials Group
Alternative Neoadjuvant Chemotherapy in Resectable and Borderline Resectable Pancreatic Cancer
Benaroya Research Institute
An Open-label, Phase I/II Study of the Pan-immunotherapy in Patients With Local Advanced/Metastatic Pancreatic Cancer
Chinese PLA General Hospital
A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
Lee's Pharmaceutical Limited
Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer
Fudan University
Nivolumab Adding on Gemcitabine/S-1 in Metastatic Pancreatic Cancer
National Taiwan University Hospital
Intra-arterial Versus Intravenous Chemotherapy for Locally Advanced Pancreatic Cancer
Fudan University
Study of Gemcitabine Plus Nab-paclitaxel Versus S1 Plus Nab-paclitaxel in Metastatic Adenocarcinoma of the Pancreas
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Study of CG200745 PPA in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer
CrystalGenomics, Inc.
Nab-paclitaxel and Gemcitabine in Metastatic Pancreatic Cancer
Fudan University
A Trial of NS/GEMOX Chemotherapy in Patients With Untreated Pancreatic Cancer ( HZ-NS/GEMOX-PC )
Harbin Medical University
PELICAN
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
xenoZ
University of Pisa
ASAGPAC
Peking University
AFFECT
Ludwig-Maximilians - University of Munich
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
A Study of CPI-613 With Gemcitabine and Nab-paclitaxel for Patients With Advanced or Metastatic Pancreatic Cancer
Atlantic Health System
The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer
Seoul National University Hospital
HEAT
Klinikum der Universitaet Muenchen, Grosshadern
Safety Feasibility and Effect of TTFields (150 kHz) Concomitant With Gemcitabine or Concomitant With Gemcitabine Plus Nab-paclitaxel for Front-line Therapy of Advanced Pancreatic Adenocarcinoma (PANOVA)
NovoCure Ltd.
Phase 2 Trial of Gemcitabine vs S-1 vs Gemcitabine Plus Nab-paclitaxel as Adjuvant Chemotherapy of Post-operative Pancreatic Cancer Patients
Chinese PLA General Hospital
HST
Tianjin Medical University Cancer Institute and Hospital
Study of Stereotactic Body Radiation Therapy for Patients After Radical Resection of Pancreatic Cancer With Advanced Stages (T3 or N1)
Second Affiliated Hospital, School of Medicine, Zhejiang University
AFUGEM
GERCOR - Multidisciplinary Oncology Cooperative Group
A Phase III Study to Assess the Efficacy and Safety of GV1001-Gem/Cap vs Gem/Cap in Pancreatic Cancer Patients
Samsung Pharmaceutical Co., Ltd.
AKT
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Second-Line Adjuvant Therapy With Nab-Paclitaxel Plus Gemcitabine Versus Oxaliplatin Plus Folinic Acid and Fluorouracil for Gemcitabine-Refractory Pancreatic Cancer After Curative Resection
Fudan University
OECTAPGAMPC
Tianjin Medical University Cancer Institute and Hospital
Phase I Study of Neoadjuvant Chemotherapy for Patients With Borderline Resectable Pancreatic Cancer.
Wakayama Medical University
Adjuvant Gemcitabine Versus Gemcitabine With Chemoradiation in Pancreatic Adenocarcinoma With R1 Resection and/or Positive Lymph Nodes
Peking Union Medical College Hospital
A Study of Dexanabinol in Combination With Chemotherapy in Patients With Advanced Tumours
e-Therapeutics PLC
A Study of Pre-Operative Cyberknife in Patients With Potentially Resectable Pancreas Cancer
The Cooper Health System